LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the company’s clinical programs in anterior and posterior ocular disease as part of the Ophthalmology Innovation Summit’s Virtual Public Company Showcase on Thursday, July 16, 2020. Dr. Brady’s presentation is scheduled for 1:40 to 1:50 p.m. ET.

As part of the Showcase, Dr. Brady also will participate in the Ophthalmology Outlook Panel moderated by Emmett T. Cunningham Jr., M.D., Ph.D. (Read more…), MPH, Senior Managing Director for Blackstone Life Sciences. The panel discussion is scheduled for 2:20 to 3:00 p.m. ET.

A webcast of Dr. Brady’s presentation and the Ophthalmology Outlook Panel will be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com or https://hopin.to/events/ois-virtual-public-company-showcase. Registration is required; suggested log-in is at least 10 minutes prior to the scheduled event. After the webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

Contacts

Corporate Contact:
David McMullin

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

[email protected]

Investor & Media Contact:
Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

[email protected]

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the company’s clinical programs in anterior and posterior ocular disease as part of the Ophthalmology Innovation Summit’s Virtual Public Company Showcase on Thursday, July 16, 2020. Dr. Brady’s presentation is scheduled for 1:40 to 1:50 p.m. ET.

As part of the Showcase, Dr. Brady also will participate in the Ophthalmology Outlook Panel moderated by Emmett T. Cunningham Jr., M.D., Ph.D. (Read more…), MPH, Senior Managing Director for Blackstone Life Sciences. The panel discussion is scheduled for 2:20 to 3:00 p.m. ET.

A webcast of Dr. Brady’s presentation and the Ophthalmology Outlook Panel will be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com or https://hopin.to/events/ois-virtual-public-company-showcase. Registration is required; suggested log-in is at least 10 minutes prior to the scheduled event. After the webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

Contacts

Corporate Contact:
David McMullin

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

[email protected]

Investor & Media Contact:
Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

[email protected]